This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-09 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
The medication is taken orally as a prodrug, ixazomib citrate, which is a boronic ester; this ester rapidly hydrolyzes under physiological conditions to its biologically active form, ixazomib, a boronic acid. Absolute bioavailability is 58%, and highest blood plasma concentrations of ixazomib are reached after one hour. Plasma protein binding is 99%. The substance is metabolized by many CYP enzymes (percentages in vitro, at higher than clinical concentrations: CYP3A4 42.3%, CYP1A2 26.1%, CYP2B6 16.0%, CYP2C8 6.0%, CYP2D6 4.8%, CYP2C9 4.8%, CYP2C9 <1%) as well as non-CYP enzymes, which could explain the low interaction potential. Clearance is about 1.86 litres per hour with a wide variability of 44% between individuals, and plasma half-life is 9.5 days. 62% of ixazomib and its metabolites are excreted via the urine (of which less than 3.5% in unchanged form) and 22% via the faeces.
== Radioactive primordial nuclides == Although it is estimated that about 35 primordial nuclides are radioactive (see list of nuclides), it is very hard to determine the exact number of radioactive primordials, as there are many extremely long-lived nuclides whose half-lives are still unknown; in fact, all nuclides heavier than dysprosium-164 are theoretically radioactive. For example, it is predicted theoretically that all isotopes of tungsten, including those indicated by even the most modern empirical methods to be stable, must be radioactive to alpha decay, but this can be detected experimentally only for 180W. Similarly, all four primordial isotopes of lead are expected to decay to mercury, but the predicted half-lives are so long (some exceeding 10100 years) that such decays could hardly be observed in the near future. Nevertheless, the number of nuclides with half-lives so long that they cannot be measured with present instruments—and are considered from this viewpoint to be stable nuclides—is limited. Even when a "stable" nuclide is found to be radioactive, it merely moves from the stable to the unstable list of primordials, and the total number of primordial nuclides remains unchanged. For practical purposes, such nuclides, whose radioactivity is not detectable by ordinary means, may be considered stable for all purposes outside specialized research. These 35 primordial radionuclides are isotopes of 28 elements (cadmium, neodymium, osmium, samarium, tellurium, uranium, and xenon each have two primordial radioisotopes).
=== Semilente insulin === Semilente insulin was an insulin from the lente family of insulin that was derived from pork. It had smaller crystals than untralente, so it was absorbed faster, and therefore had a shorter duration of action which was similar to that of regular insulin. Like the other lente insulins, it was phased out in the early 2000s. It was produced by Lilly under the name Semilente Iletin I.
Sources: en.wikipedia.org
== Adverse effects == Common adverse effects are constipation and nausea, but rates of discontinuation due to constipation were low for both eluxadoline and placebo. Rare adverse effects: fatigue, bronchitis, viral gastroenteritis. Rare serious adverse effects include pancreatitis with a general incidence of 0.3%: higher incidence with 100 mg dose (0.3%) than with 75 mg dose (0.2%). The risk is even greater in those who do not have a gallbladder and the medication is not recommended in this group. In March 2017, the U.S. Food and Drug Administration issued a safety alert for eluxadoline concerning an increased risk of serious pancreatitis in patients without a gallbladder. An FDA review found that in such patients, spasm of the sphincter of Oddi may lead to severe pancreatitis. The FDA reported that in some cases symptoms have occurred with just one or two doses at the recommended dosage for patients without a gallbladder (75 mg). Of two deaths associated with eluxadoline reported up to February 2017, both occurred in patients without a gallbladder.
== Research == The research name of emapalumab was NI-0501. A phase II/III trial began in 2013 and is ongoing as of August 2018. The trial targets patients under the age of 18 who have failed to improve on conventional treatments. This study was realised in the context of an EU-funded FP7 project, named FIGHT-HLH (306124).
On March 23, Twitter announced it would remove blue checkmarks from "legacy" verified accounts on April 1, or April Fools' Day. Twitter subsequently stopped distinguishing Twitter Blue subscribers from legacy verified accounts on April 2. On April 19, the Twitter Verified account tweeted that, on April 20, legacy verified checkmarks would disappear, in apparent reference to the cannabis slang number 420; Musk had previously tweeted about the April 20 date on April 11. Despite skepticism due to the date, Twitter began removing legacy checkmarks on April 20, 2023. Among those that lost their verified status included Cristiano Ronaldo and Beyoncé. Actress Halle Berry posted a meme commemorating the loss of her blue checkmark. Several figures, such as Stephen King, noted that they had not paid for verification and—in King's case—had not added a phone number to their account. While some users, such as Eliot Higgins of Bellingcat appear to have been given verification for free, others, such as actor Ryan Reynolds—whose Twitter account has 21 million followers—do not. NBC News noted that legacy verified accounts still appeared in search results filtering for just verified users. The Washington Post noted that several deceased individuals, such as basketball player Kobe Bryant, actor Chadwick Boseman, celebrity chef Anthony Bourdain, and Linkin Park vocalist Chester Bennington had a blue checkmark. Other figures with blue checkmarks include singer Michael Jackson, rapper Mac Miller, and senator John McCain.
Sources: en.wikipedia.org
=== 4th Congress (1986) === The Political Report to the Fourth Congress (Nov. 1986) stated "For the first time there is a possibility of building a truly revolutionary party on the basis of the objective communist movement. That movement is nothing less than the galvanizing struggles of 50 million dispossessed, hungry, homeless and unemployed—the most oppressed and exploited workers. This must be the firm foundation of our Party.” Here the CLP begins to clearly move away from the 3rd International conception of the industrial workers as the foundation of the communist party. With the application of electronics to the productive process, which accelerated in the 1970s and 80s, the industrial workers began to disappear from the workforce. Many left groups moved to base themselves in whatever unions remained, in spite of the fact that both public and private sector unions were radically declining in membership. The CLP began to seriously grapple with the transformation that was occurring within the working class. In the pamphlet, "Documents of the Fourth Congress,” the article "Explanation of the Party Program” quotes an 1890 letter written by Engels: "It is far more important that the movement should spread, proceed harmoniously, take root and embrace as much as possible the whole American proletariat than that it should start and proceed, from the beginning, on theoretically perfectly correct lines. There is no better road to theoretical clearness of comprehension than to learn by one’s own mistakes.
=== Replacement by cysteine in mammals === Most mammal selenoproteins have a small amount (about 10%) of the selenocystine replaced by cystine, increasing to 50% on selenium-deficient diets. This is achieved by SLA/LP accepting thiophosphate instead of selenophosphate, thereby converting the phosphoseryl into a regular cystyl.
== Synthesis == Like all bacterial extracellular proteases thermolysin is first synthesised by the bacterium as a pre-proenzyme. Thermolysin is synthesized as a pre-proenzyme consisting of a signal peptide 28 amino acids long, a pro-peptide 204 amino acids long and the mature enzyme itself 316 amino acids in length. The signal peptide acts as a signal for translocation of pre-prothermolysin to the bacterial cytoplasmic membrane. In the periplasm pre-prothermolysin is then processed into prothermolysin by a signal peptidase. The prosequence then acts as a molecular chaperone and leads to autocleavage of the peptide bond linking pro and mature sequences. The mature protein is then secreted into the extracellular medium.
=== Exercise === Exercise has been shown to improve insulin sensitivity in humans with metabolic syndrome. Increased exercise is therefore recommended in horses with EMS, assuming laminitis does not restrict activity levels. Current recommendations include 2–3 sessions a week, of 20–30 minutes of work, with gradual increase in duration and intensity.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.